Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

78 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Cost of illness of cystic fibrosis in Germany: results from a large cystic fibrosis centre.
Heimeshoff M, Hollmeyer H, Schreyögg J, Tiemann O, Staab D. Heimeshoff M, et al. Among authors: schreyogg j. Pharmacoeconomics. 2012 Sep 1;30(9):763-77. doi: 10.2165/11588870-000000000-00000. Pharmacoeconomics. 2012. PMID: 22690685
Determining the "Health Benefit Basket" of the Statutory Health Insurance scheme in Germany: methodologies and criteria.
Busse R, Stargardt T, Schreyögg J. Busse R, et al. Among authors: schreyogg j. Eur J Health Econ. 2005 Dec;Suppl(Suppl 1):30-6. doi: 10.1007/s10198-005-0316-z. Eur J Health Econ. 2005. PMID: 16270210 Free PMC article. Review.
Regulation of pharmaceutical markets in Germany: improving efficiency and controlling expenditures?
Busse R, Schreyögg J, Henke KD. Busse R, et al. Among authors: schreyogg j. Int J Health Plann Manage. 2005 Oct-Dec;20(4):329-49. doi: 10.1002/hpm.818. Int J Health Plann Manage. 2005. PMID: 16335081
Cost-effectiveness analysis of telemedical devices for pre-clinical traffic accident emergency rescue in Germany.
Auerbach H, Schreyögg J, Busse R. Auerbach H, et al. Among authors: schreyogg j. Technol Health Care. 2006;14(3):189-97. Technol Health Care. 2006. PMID: 16971757
Hospitalisation costs of cystic fibrosis.
Schreyögg J, Hollmeyer H, Bluemel M, Staab D, Busse R. Schreyögg J, et al. Pharmacoeconomics. 2006;24(10):999-1009. doi: 10.2165/00019053-200624100-00007. Pharmacoeconomics. 2006. PMID: 17002482
Cost accounting to determine prices: how well do prices reflect costs in the German DRG-system?
Schreyögg J, Tiemann O, Busse R. Schreyögg J, et al. Health Care Manag Sci. 2006 Aug;9(3):269-79. doi: 10.1007/s10729-006-9094-0. Health Care Manag Sci. 2006. PMID: 17016933
Impact of cross-reference pricing on pharmaceutical prices: manufacturers' pricing strategies and price regulation.
Stargardt T, Schreyögg J. Stargardt T, et al. Among authors: schreyogg j. Appl Health Econ Health Policy. 2006;5(4):235-47. doi: 10.2165/00148365-200605040-00005. Appl Health Econ Health Policy. 2006. PMID: 17249840
Pricing behaviour of pharmacies after market deregulation for OTC drugs: the case of Germany.
Stargardt T, Schreyögg J, Busse R. Stargardt T, et al. Among authors: schreyogg j. Health Policy. 2007 Nov;84(1):30-8. doi: 10.1016/j.healthpol.2007.04.006. Epub 2007 Jun 5. Health Policy. 2007. PMID: 17553587
Cross-country comparisons of costs: the use of episode-specific transitive purchasing power parities with standardised cost categories.
Schreyögg J, Tiemann O, Stargardt T, Busse R. Schreyögg J, et al. Health Econ. 2008 Jan;17(1 Suppl):S95-103. doi: 10.1002/hec.1327. Health Econ. 2008. PMID: 18186031
Performance of reimbursement schemes in valuation of technologies: the example of magnetic resonance imaging.
Blankart R, Schreyögg J, Busse R. Blankart R, et al. Among authors: schreyogg j. Technol Health Care. 2008;16(3):171-82. Technol Health Care. 2008. PMID: 18641437
78 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page
Feedback